Idorsia Ltd.
ISIN CH0363463438
|WKN A2DTEB
Market cap (in EUR)
319.52 m
Country
Switzerland
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Idorsia Ltd. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of medicines for medical needs. It operates through the following geographical segments: Switzerland, United States, Japan, and Rest of World. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Switzerland
Financials
Key metrics
| Market capitalisation, EUR | 319.52 m |
| EPS, EUR | -1.34 |
| P/B ratio | - |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 118.19 m |
| Net income, EUR | -277.09 m |
| Profit margin | -234.43% |
What ETF is Idorsia Ltd. in?
There are 10 ETFs which contain Idorsia Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Idorsia Ltd. is the L&G Pharma Breakthrough UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
